Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-010789
Filing Date
2025-08-07
Accepted
2025-08-07 16:31:13
Documents
66
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20250630x10q.htm   iXBRL 10-Q 1962170
2 EX-31.1 acrs-20250630xex31d1.htm EX-31.1 15491
3 EX-31.2 acrs-20250630xex31d2.htm EX-31.2 15556
4 EX-32.1 acrs-20250630xex32d1.htm EX-32.1 9427
  Complete submission text file 0001558370-25-010789.txt   8491435

Data Files

Seq Description Document Type Size
5 EX-101.SCH acrs-20250630.xsd EX-101.SCH 45023
6 EX-101.CAL acrs-20250630_cal.xml EX-101.CAL 44084
7 EX-101.DEF acrs-20250630_def.xml EX-101.DEF 184703
8 EX-101.LAB acrs-20250630_lab.xml EX-101.LAB 442593
9 EX-101.PRE acrs-20250630_pre.xml EX-101.PRE 303079
69 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20250630x10q_htm.xml XML 1834669
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 251194687
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)